دورية أكاديمية
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
| العنوان: | Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) |
|---|---|
| المؤلفون: | Orsi, Giulia, Cavaliere, Alessandro, Tortora, Giampaolo, Lonardi, Sara, Macchini, Marina, Di Marco, Mariacristina, Giordano, Guido, Vasile, Enrico, Scartozzi, Mario, Bozzarelli, Silvia, Noventa, Silvia, Rodriquenz, Maria Grazia, Militello, Anna Maria, Rapposelli, Ilario Giovanni, Garajova, Ingrid, De Lorenzo, Stefania, Merelli, Barbara, Bittoni, Alessandro, Salvatore, Lisa, Procaccio, Letizia, Paratore, Chiara, Spallanzani, Andrea, Peretti, Umberto, Niger, Monica, Giommoni, Elisa, Bernardini, Ilaria, Tamburini, Emiliano, Bernardino, Katia, Forti, Laura, Valente, Maria Maddalena, Cascinu, Stefano, Milella, Michele, Reni, Michele |
| المساهمون: | Orsi, Giulia, Cavaliere, Alessandro, Tortora, Giampaolo, Lonardi, Sara, Macchini, Marina, Di Marco, Mariacristina, Giordano, Guido, Vasile, Enrico, Scartozzi, Mario, Bozzarelli, Silvia, Noventa, Silvia, Rodriquenz, Maria Grazia, Militello, Anna Maria, Rapposelli, Ilario Giovanni, Garajova, Ingrid, De Lorenzo, Stefania, Merelli, Barbara, Bittoni, Alessandro, Salvatore, Lisa, Procaccio, Letizia, Paratore, Chiara, Spallanzani, Andrea, Peretti, Umberto, Niger, Monica, Giommoni, Elisa, Bernardini, Ilaria, Tamburini, Emiliano, Bernardino, Katia, Forti, Laura, Valente, Maria Maddalena, Cascinu, Stefano, Milella, Michele, Reni, Michele |
| سنة النشر: | 2023 |
| المجموعة: | Università degli Studi di Cagliari: UNICA IRIS |
| مصطلحات موضوعية: | Pancreatic cancer |
| الوصف: | Background: Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second-line therapy (2LT) outcome in this setting is lacking. Methods: Data of gBRCA1-2pv metastatic PDAC patients treated with chemotherapy were collected. A primary analysis of 2LT RECIST response, median progression-free survival (mPFS2) and overall survival (mOS2), was performed. A secondary analysis addressed the impact of timing of platinum introduction on the outcome of patients receiving at least a first-line combination chemotherapy (1LT). Results: Eighty-four gBRCA1-2pv metastatic PDAC patients were enrolled. The primary analysis, including 43 patients, highlighted a significant improvement of mPFS2 and a doubled response rate, in the platinum-based 2LT subgroup as compared to the platinum-free (8.8 versus 3.7 months, p = 0.013). Seventy-seven patients were included in the secondary analysis. Median PFS1 of 3- and 4-drug platinum-based 1LT significantly outperformed both platinum-free combinations and platinum-based doublets (11.4 versus 6.4 versus 7.9 months, p = 0.01). Albeit still immature, data on mOS paralleled those on mPFS. Conclusions: This study highlighted the beneficial role of platinum agents in gBRCA1-2pv PDAC patients also in second-line treatment setting. However, our data suggest that early use of 3- and 4-drug platinum-based chemotherapy combinations provides a survival outcome advantage. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36482190; info:eu-repo/semantics/altIdentifier/wos/WOS:000901534800003; volume:128; issue:5; firstpage:877; lastpage:885; numberofpages:9; journal:BRITISH JOURNAL OF CANCER; https://hdl.handle.net/11584/356508Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85143587842; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977912Test/ |
| DOI: | 10.1038/s41416-022-02086-w |
| الإتاحة: | https://doi.org/10.1038/s41416-022-02086-wTest https://hdl.handle.net/11584/356508Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977912Test/ |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.AFC4177D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41416-022-02086-w |
|---|